Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

By J. Feld, Kris V. Kowdley, E. Coakley, S. Sigal, D. Nelson, D. Crawford, O. Weiland, H. Aguilar, J. Xiong, T. Pilot‐Matias and 4 more. New England Journal of Medicine, 2014

979 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/0130f494f6458749f4457c44db9c06a599cad495

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Pawlotsky
2. G. Dusheiko
3. M. Puoti
4. A. Aghemo
5. X. Forns
6. Christoph Sarrazin

Citations in the corpus

• Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection (2017, methodology): “SAPPHIRE-l, 2014 (22) SAPPHIRE-II, 2014 (23) OPTIMIST-l, 2016 (46)”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, methodology): “In SAPPHIRE-I in treatment-naïve patients without cirrhosis treated with this combination together with ribavirin for 12 weeks, the SVR12 rates were 95% (307/322) in subtype 1a and 98% (148/151) in subtype 1b patients [40].”